Baird Maintains Outperform on Ultragenyx Pharmaceutical, Raises Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty maintains an Outperform rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $68 to $72.
May 31, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Joel Beatty maintains an Outperform rating on Ultragenyx Pharmaceutical and raises the price target from $68 to $72.
The raised price target and maintained Outperform rating from a reputable analyst are likely to positively influence investor sentiment and drive short-term price appreciation for Ultragenyx Pharmaceutical.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100